C-3HRQTolerance Bio
thymus therapeutics, immune tolerance, iPSC-derived organoids
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-3HRQ
C-3HRQC-3HRQthymus therapeutics, immune tolerance, iPSC-derived organoids
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TRACT Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies TRACT Therapeutics TRACT Therapeutics is dedicated to developing innovative, personalized cellular therapies to improve transplant medicine and autoimmune disease treatment. Their flagship product, TregCel™, utilizes a patient's own regulatory T cells to establish immune tolerance, potentially reducing or eliminating the need for lifelong immunosuppressive drugs. The company aims to enhance long-term organ transplant success and treat autoimmune disorde
Scientific Sessions Accreditation Statements | American Diabetes Association 5) ? true : false; " > Skip to Main content Diabetes.org Diabetes Food Hub Conversion Calculator Donate Join ADA Online Store Contact Us keywords Search url Leave this field blank Open main menu Standards of Care Link title here Link copy to come here bold Meetings Scientific Sessions Registration Agenda Abstracts FAQs Innovation Challenge ADA Meeting News Get 2027 Meeting Updates bold bold Clinical Update Conference 2027 Call for Session Proposals Diabetes Technology Meeting bold Registration Agenda Hotel Information … or the 2027 Clinical Update Conference.The submission window closes on July 31. Submit your proposal today! 2026 Diabetes Technology Meeting (DTM) Explore what’s next in diabetes tech at the DTM, taking place October 27–29 in Washington, DC. Early bird registration opens April 15! ADA Meeting News Catch up on the transformative science presented during the Scientific Sessions. bold Clinical Support Clinical Support Patient Education Library Nutrition & Wellness Vaccinatio … webinars bold Research & Grants Research & Grants Funding Opportunities Grant Management Portal Information for Current Grantees bold Resources for Researchers Contact Us FAQs Pathway to Stop Diabetes® Learn about ADA's Pathway to Stop Diabetes initiative Grant Awardee Resources Information for Current Grantees The ADA’s Scientific Sessions Join us at the premier diabetes conference where leading experts and peers will share the latest findings in research, prevention … lizing treatment protocols for the management of hyperglycemia and hypoglycemia Apply clinical decision-making tools to the assessment and treatment of diabetes-related complications Develop a more aggressive and effective physiological, psychological, and behavioral treatment plan for patients with diabetes Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes Discuss proven education strategies for increasing the impact of diabetes edu … lated to obesity. Please request a copy of your transcript if you would like to submit it to ABOM. Physicians for ABIM Maintenance of Certification Image Successful completion of this CME activity, which includes participation in the evaluation component, enables participants to earn up to 29.5 medical-knowledge-only MOC points in the Americ
Speakers - 9th Antigen-Specific Immune Tolerance Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 meeting. Returning March, 2026 | Boston, MA About About Event Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Partners Take Part Register Interest Contact Us 2026 Event Guide Register Interest About About Event Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Partners Take Part Register Interest Contact Us Returning Mar
Tolerance Bio | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Are About Us Meet … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Tolerance Bio Back to Search Tolerance Bio www.tolerancebio.com About Biotechnology company dedicated to increasing healthspan by restoring and preserving the function of the … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
What an extraordinary moment to watch my friends and colleagues be honored in Stockholm. Their discoveries have changed our understand of immune tolerance and began the revolution to develop new… | Jeffrey Bluestone LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at … mbled to have had the chance to celebrate with Fred, Shimon and Mary. The Nobel Prize 1,178,335 followers 6mo Congratulations to the 2025 medicine laureates! Watch the very moment Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi received their Nobel Prize diplomas and medals during the 2025 Nobel Prize award ceremony. #NobelPrize 222 4 Comments Like Comment Share Copy LinkedIn Facebook X Francisco Leon 6mo Report this comment So well deserved. And your own contributions to sc
Tolerance Bio launches with $17.2 million seed funding | Biotechnology | The Pharmaletter Saturday 27 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hemat
Francisco Leon - Lorraine Marchand Skip to content Lorraine Marchand Author. Speaker. Innovation Consultant. Home Consulting Speaking Writing Articles Books About Press Contact Innovators Circle Home Consulting Speaking Writing Articles Books About Press Contact Innovators Circle Linkedin-in Back to Innovators Circle Prev Previous Mark Powell Next Brian Elliott Next Francisco Leon CEO, Tolerance Bio Francisco Leon, MD, PhD, is the Founder and CEO of Tolerance Bio, focused on restoring, manipulating, and preserving the thymus to address immune diseases. Francisco is a clinical and basic immunol
Francisco Leon - 6th Age-Related Disease Therapeutics Summit Skip to content THIS EVENT HAS BEEN CANCELLED About About Event Hanson Wade Products What’s On? Full Event Guide Why Partner Why Partner Media Partners Take Part Register Interest Contact Us Register Interest About About Event Hanson Wade Products What’s On? Full Event Guide Why Partner Why Partner Media Partners Take Part Register Interest Contact Us THIS EVENT HAS BEEN CANCELLED Register Interest Francisco Leon Francisco Leon Chief Executive Officer, Founder & Chairman Tolerance Bio Seminars Thursday 29th January 2026 P
Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Back to Industry News & Announcements Tol … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
Tolerance Bio: Pioneering Immune Tolerance with Thymus-Based Therapies Backed by $20.2M Seed Financing | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up Greater Philadelphia People Editorial Tolerance Bio: Pioneering Immune Tolerance with Thymus-Based Therapies Backed by $20.2M Seed Financing By Bryan Kennedy · Published December 20, 2024 · 8 min read · Greater Philadelphia ← News / Tolerance Bio: Pioneering Immune Tolerance with Thymus-Based Therapies… Tolerance Bio is … hia People In Conversation The Future of Biopharma Depends on What We Choose to Fund April 29, 2026 Explore News Events Resources & Tools Company About Us Team History Contact © 2026 BioBuzz Networks. All rights reserved. Privacy Policy · Terms of Service · Cookie Settings We use cookies to give you the best experience on our website. Choose which categories you want to allow. Got it Cookie Preferences Choose which categories you want to allow. Strictly
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Sachs Associates Forum: Neurostimulation and Brain Health Innovation | Dr Antonella Santuccione Chadha posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Conti
Tolerance Bio Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market Chin
Tolerance Bio, Inc. | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies Tolerance Bio, Inc. Tolerance Bio, Inc. Private Philadelphia, Pennsylvania Healthcare & Life Sciences https://tolerancebio.com Last Round Early Stage VC Jun 18, 2026 Total Funding Raised $20.2M Company Overview Tolerance Bio, Inc. is a biopharmaceutical company developing therapies focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases. Secto
Tolerance Bio | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Tolerance Bio Tolerance Bio is dedicated to increasing healthspan by restoring and preserving the function of the thymus. Categories Active View Project Hula Therapeutics Spirovant Sciences © 2024 BioAdvance. All Rights Reserved. | Privacy Policy | Site by Loudmark 101 West Elm Street, Suite 330, Conshohocken, PA 19428 | (610) 230-0544 Close Menu About Team Portfolio News Contact linkedin patreon
Tolerance Bio - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Show more me
BioCentury - Tolerance Bio: Rejuvenating the thymus This Edition ARTICLE | Emerging Company Profile Tolerance Bio: Rejuvenating the thymus Starting with congenital athymia, former Provention Bio team aims to restore immune tolerance — with broader implications for lifespan extension By Danielle Golovin, Senior Biopharma Analyst January 15, 2026 9:01 PM UTC The Provention Bio team is back as Tolerance Bio for a second round of tackling immune tolerance, this time going upstream of T cells with therapies designed to preserve thymus function. While its first goal is to treat congenital athymia, t
BioCentury - Science Spotlight: Reducing immune rejection of stem cell-derived therapies This Edition ARTICLE | Discovery & Translation Science Spotlight: Reducing immune rejection of stem cell-derived therapies BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos By Danielle Golovin, Senior Biopharma Analyst November 27, 2024 11:13 PM UTC Collaborators from Medical University of South Carolina and University of Florida , including Tolerance Bio Inc. co-founder Holger Russ, reported a method to reduce immune-mediate
Q4 2024 Newsletter | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Are About Us … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Q4 Newsletter 2024 Q4 Newsletter 2024 President’s Message Life Sciences Pennsylvania closed out 2024 welcoming 119 new organizations to the membership, marking our tota … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
About Us — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our Team Scientific Advisory Board … linical Immunology Societies (FOCiS) from 2022-2024, a recipient of the Medawar Prize and a member of the National Academy of Medicine. Camillo Ricordi, MD, FNAI Dr. Camillo Ricordi, MD, FNAI , is Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell … organizations, Dr. Ricordi has received numerous accolades, including the World Prize in Surgery, the American Diabetes Association’s Outstanding Scientific Achievement Award, the Leonardo Da Vinci Award, and induction into the National Academy of Inventors. His extensive contributions include over 1,170 publications, 58,000 citations, 28 patents, and the bestselling book The Healthspan Code . JEROME RITZ, MD Dr. Jerome Ritz, MD ’s research focuses on immune reconstitution af
Tolerance Bio, Inc., cierra una ronda de financiación de 17,2 millones de dólares para avanzar en terapias basadas en el timo para enfermedades inmunomediadas - Columbus Venture Partners Portal del inversor English Español Track Record Portfolio Fondos Equipo Noticias Contacto Portal del inversor Español English < Volver Tolerance Bio, Inc., cierra una ronda de financiación de 17,2 millones de dólares para avanzar en terapias basadas en el timo para enfermedades inmunomediadas 16 de octubre de 2024 Bajo el liderazgo del innovador del sector Francisco León, M.D., Ph.D., Tolerance Bio está de
Francisco Leon - Tolerance Bio | WEHI Skip to: Home Content Footer navigation WEHI.TV What’s on Art of Science Events Discovery tours News Research Our research Finding better ways of detecting and treating a wide range of diseases, and helping our community to live long and healthy lives. Overview Diseases Areas of research Technologies Researchers and labs Collaborative centres Research facilities Clinical trials Business development and ventures About About WEHI Where the world’s brightest minds collaborate and innovate to make discoveries that will help us to live healthier for longe … upporters and more. First name (Required) Last name (Required) Email (Required) Submit Δ Illuminate Autumn 2026 View the current issue - The Walter and Eliza Hall Institute of Medical Research 1G, Royal Parade, Parkville Victoria, 3052, Australia (03) 9345 2555 ABN 12 004 251 423 Connect with WEHI Business development and ventures Contact us Illuminate Newsletter Governance & Policy Funding Policies Statements Ethics and integrity Advocacy Terms of use Information Sc
About Us — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our Team Scientific Advisory Board … studying developmental immunology and lymphocyte cytotoxicity, and completed a fellowship at Memorial Sloan Kettering Cancer Center. Immunology Research Lead Carina Meyer, PhD Carina Meyer, PhD, is a bioanalytical scientist specializing in cell therapy development. At HebeCell Corp., she led assay development for stem cell-derived NK cell therapies, and supported the transition from R&D to GMP manufacturing. An expert in flow cytometry, qPCR, and cytotoxicity assays, she
%PDF-1.6 %���� 7013 0 obj > endobj 7030 0 obj >/Filter/FlateDecode/ID[ ]/Index[7013 25]/Info 7012 0 R/Length 97/Prev 1638160/Root 7014 0 R/Size 7038/Type/XRef/W[1 3 1]>>stream h�bbd```b``M��/�d�dY"���d3�4.�"b Rc�db�R��"�@��H c�H�8D���ߎ� L� �_@"@p����� `�r6 endstream endobj startxref 0 %%EOF 7037 0 obj >stream h��TILa~����t�*�M ��#ƈ�4RS��B1��\�@b�S�PMH�I9 �7�QS�=I%r 1���`Ћ���L( 0 ��cBJ*LE >/Metadata 239 0 R/OCProperties >/OCGs[7031 0 R]>>/Outlines 274 0 R/PageLayout/SinglePage/Pages 6999 0 R/StructTreeRoot 383 0 R/Type/Catalog>> endobj 7015 0 obj >/ExtGState >/ … :bd20fa3c-5d92-4794-b9a6-513636d45311 uuid:337a9c06-0c71-4c8b-9e76-0fe2305d2e2a application/pdf Cell, Gene, & RNA Therapy Landscape Nguyen-Jatkoe, Ly Adobe PDF Library 24.5.96 0x010100985091CA06F37C4FA8620137FD09A28E true 2021-10-21T20:39:20Z Privileged e1b4a6d7-967f-4d55-9d13-d94940dabb24 2567d566-604c-408a-8a60-55d0dc9d9d6b 5b676819-73a2-4186-881c-90f78c7294ca 0 endstream endobj 240 0 obj >stream hޜ��N1 �_�o���?K�k(iN':Dq+D����'�qVB N{�̮�/N��fF�J�b]���#$܍�X7��t�(�n
79 T-Cells Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas T-Cells 78 Employers in 103 locations Employers working on T-Cells work in 43 other areas Displaying 1 - 15 of 43 related areas Show: 15 50 All Cell and Gene Therapy (47) Immunotherapy (35) Cancer Therapeutics (23) Antibodies (14) CAR-T (12) Immunology (10) Autoimmunity (9) Cance
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma October 28, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Patient-specific human immune system-bearing mouse model created by implanting human thymic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trend … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics September 9, 2025 | 3 min read Twitter LinkedIn Facebook Email Print PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to ext … y is the next frontier in RNA therapeutics,” commented Dr. Drew Weissman, Nobel Prize Laureate, pioneer of mRNA technology, and Co-Founder of ZipCode Bio. “Each advance in nucleic acid therapeutics has been built on decades of careful science. By partnering with Tolerance Bio, we have the opportunity to extend this work into thymus biology, an area with profound implications for immune health.” The collaboration will initially focus on preclinical development of thymus-target … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Dev … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases December 20, 2024 | 8 min read Twitter LinkedIn Facebook Email Print World-class leaders in the thymus, immunology, oncology, cell therapy, and … linical Immunology Societies (FOCiS) from 2022-2024, a recipient of the Medawar Prize, and a member of the National Academy of Medicine. Dr. Camillo Ricordi, M.D., FNAI, is a Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant Center and … organizations, Dr. Ricordi has received numerous accolades, including the World Prize in Surgery, the American Diabetes Association’s Outstanding Scientific Achievement Award, the Leonardo Da Vinci Award, and induction into the National Academy of Inventors. His extensive contributions include over 1,170 publications, 58,000 citations, 28 patents, and the bestselling book The Healthspan Code . Dr. Jerome Ritz, M.D. ’s research focuses on immune reconstitution after hematopoie … ollow us on LinkedIn . About Pacific 8 Ventures Pacific 8 Ventures is a venture fund focusing at the nexus of new technology platforms and medicine. Pacific 8 Ventures typically backs transformative biotech and healthcare founders at the early stages. For more information, please visit: www.pac8.com Contacts Media Contact Kate Burdick Inizio Evok
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases October 16, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Led by industry innovator Francisco Leon, M.D., Ph.D., Tolerance Bio is developing thymus preservation, regen … Criteria Bio Ventures Criteria Bio Ventures is a leading life sciences venture fund investing in transformative companies to shape the future of healthcare. We partner with driven entrepreneurs and fellow investors to build innovative companies with the potential to transform patients’ lives. Criteria Bio Ventures invests in global biotech companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe. Crit … es.com/ About BioAdvance BioAdvance is an $80-million early-stage life sciences fund with a focus on the mid-Atlantic region, investing in companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed more than $73 million in funding to approximately 115 organizations developing more than 208 products in the diagnostics, therapeutic, medtech, research tools, and digital health sectors. BioAdvance portfolio comp … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BioPharma Updates 15th September, 2025 | SciLeads Features 3 2 Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions 3 2 Sales Marketing Data Analytics CROs API AI Partner Program Pricing Events Resources 3 2 Blog Case Studies eBooks Webinars Newsletter Company 3 2 About Us Careers Testimonials Partners Press & News Contact Login Free Trial a M Features 3 2 Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions 3 2 Sales Marketing Data Analytics CROs API AI Partner Pro … international presence. NanoNewron (NJ, USA) received a $2.5M NIH STTR Phase 2 grant to advance its NN-840 program for Alzheimer’s disease, supporting IND-enabling studies ahead of a planned filing next year. Inkocell Therapeutics (Lausanne, Switzerland) received a $168K grant from Venture Kick to advance its next-generation NK-tailored CAR cell therapy platform aimed at developing scalable, safer, and off-the-shelf treatments for cancer and other serious diseases.&nbs … . Valo Health (MA, USA) received an undisclosed Michael J. Fox Foundation grant to investigate NOD2 as a Parkinson’s target using human datasets and AI to determine optimal target modulation. Dewpoint Therapeutics (MA, USA) raised an undisclosed amount in Series D funding to advance its condensate modulator DPTX3186 into clinical trials for gastric cancer and accelerate development of additional c-mod programs. Emerging Ridge Biotechnologies (CA, USA) emerge … ounced pricing of a private placement of ~$100M to advance its SYNGAP1 program, fund R&D, and support working capital and general corporate purposes. Lucid Diagnostics (NY, USA) announced closing of a $28.75M underwritten public offering to support working capital and general corporate purposes. SELLAS Life Sciences (NY, USA) announced the immediate exercise of warrants for $23.6M in gross proceeds, with new warrants issued in a concurrent private placement. Sirnaomics (M … utics (Melbourne, Australia) announced pricing of a $13.2M private placement to fund non-clinical studies, CMC activities, and clinical and regulatory development of ATH434 for Multiple System Atrophy, as well as for general working capital. Xanadu Bio (PA, USA) raised $11M through a private stock sale to advance its PACE nanoparticle delivery pl
Cardion GmbH - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Cardion GmbH Private Company | 1996 | Germany | 10-50 | www.cardion.cz Private Company | 1996 | Germany | 10-50 | www.cardion.cz Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 2 Drugs associated with Cardion GmbH Nitric oxide synthase gene therapy(Valentis, Inc.) Target NOS2 Mechanism NOS2 stimulants Active Org. - Originator Org. Valentis, Inc. Active Indic … ical trial of IgAN patients. Travere will engage with regulators and expects to submit a supplemental New Drug Application ("sNDA") in the first half of 2024 for full approval in the U.S. On October 26, 2023 Merck (NYSE: MRK) announced third quarter 2023 Vaxneuvance sales of $214 million. Merck previously reported Vaxneuvance sales of $168 million and $106 million in the second and first quarter of 2023, respectively. Additionally, Merck previously announced its Phase 3 clini … plc (Nasdaq: VRNA) announced that the FDA has accepted for review its New Drug Application seeking approval of ensifentrine for the maintenance treatment of patients with COPD. The FDA has assigned a PDUFA date of June 26, 2024, and is not currently planning to hold an advisory committee meeting to discuss the application. Anebulo Pharmaceuticals Inc. (Nasdaq: ANEB) announced positive feedback from the FDA following a Type B meeting in July. The FDA indicated that a single w … volunteers could potentially provide substantial evidence to support a new drug application. Adjusted Financial Measures Ligand reports adjusted net income and adjusted net income per diluted share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include share-based compensation expense, amortization of debt-related costs, amortization related to acquisitions and int … rd, the Company is required to reflect the dilutive effect of the 2023 Notes by application of the if-converted method, The 2023 Notes were fully paid off on May 15, 2023, the debt maturity date. View source version on businesswire.com: Contacts Ligand Pharmaceuticals Incorporated Simon Latimer [email protected] (858) 550-7766 Twitter: @Ligand
SAB Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 SAB Biotherapeutics, Inc. Public Company | 2014 | South Dakota, United States | 50-100 | NASDAQ: SABS | www.sab.bio Public Company | 2014 | South Dakota, United States | 50-100 | NASDAQ: SABS | www.sab.bio Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Respiratory Diseases Infectious Diseases Endocrinology and Metabolic Disease Polyclonal antibody … ation (FDA) provided clearance for the Company’s investigational new drug (IND) application to proceed with a Phase 1 clinical trial (the HUMAN trial – fully HUman anti-thymocyte biologic in first-in-MAN clinical study) evaluating SAB-142 in type 1 diabetes. Corporate Updates from Fiscal Year 2024 On August 5, 2024, the Company announced the founding of a clinical advisory board to provide expert insight and guidance to the Company in the clinical development of SAB-142. On J … zymes both in vitro and in vivo has resulted in numerous publications, patents, grant funds and private/venture capital funding. Aaron holds an MBA from the University of Florida Warrington College of Business and a PhD in Chemistry from the University of Kansas. Bryan Hassell , Ph.D. is the founder and Chief Technical Officer at Nirrin Technologies. He also served as a Principal Investigator for the U.S. Department of Defense (DOD), evaluating the innovation potential of sma … linical Immunology Societies (FOCiS) from 2022-2024, a recipient of the Medawar Prize, and a member of the National Academy of Medicine. Dr. Camillo Ricordi, M.D., FNAI, is a Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant Center and … organizations, Dr. Ricordi has received numerous accolades, including the World Prize in Surgery, the American Diabetes Association’s Outstanding Scientific Achievement Award, the Leonardo Da Vinci Award, and induction into the National Academy of Inventors. His extensive contributions include over 1,170 publications, 58,000 citations, 28 patents
Industry News & Announcements | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Ar … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Industry News & Announcements Industry News & Announcements Posted... This Week This Month Last 30 Days Last 90 Days This Year Custom Search Start Date End Date Resul … ample size for the ongoing OTC-HOPE study which could support Biologics License Application (BLA) Awarded Innovation Passport under the United Kingdom’s relaunched Innovative Licensing and Access Pathway (ILAP) Donna Lutz 1/7/2026 and leave .card-header empty--> Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership M … , DA Chris Sampson 8/5/2025 and leave .card-header empty--> MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer A biotechnology company focused on preventing the metastasis of solid tumor cancers – like prostate, breast and skin, announced today it has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). Michael Baryc … mony Biosciences 6/28/2024 and leave .card-header empty--> With $12 Million NIH Grant Renewal, Lewis Katz School of Medicine Researchers to Explore Novel Cell Mechanism in Heart Injury and Repai Temple University 6/28/2024 and leave .card-header empty--> Wistar Institute receives $10M gift for new Center for Advanced Therapeutics project The now
Praetorian Bio presents mucosal vaccines at Dentech Conference | Praetorian Bio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … reshapes the narrative. The platform’s next phase will depend on how companies apply mRNA in oncology, rare diseases, and chronic infections, where efficacy thresholds are even higher. 👉 What could this mean for the future of mRNA beyond vaccines? 💡 Follow Sadhna Bokhiria & KIRIA Research for evidence-based insights on biotech, leadership, and the future of healthcare innovation. #Moderna #Biotech #Pharma #mRNA #KIRIAResearch #KIRIA 16 2 Comments Like Comment Share Cop … AMR asset with the right progression pathway and translational roadmap. If your application to the latest antibacterial therapeutics funding round is successful, here’s an overview of the support you will receive: ✅ Dedicated PACE R&D advisors Our R&D advisors work with awardees to help progress projects with greater speed and confidence ✅ Access to a Delivery Partner Network (DPN) This brings together strength and depth in infectious disease drug and diagnostic disco … AMR R&D community. Visit our website to view our current funding round and submit your application: https://lnkd.in/eKC3HZ6H Medicines Discovery Catapult | LifeArc | Innovate UK #AMR 43 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in The Indian Practitioner 2,214 followers 7mo Report this post MEDICAL UPDATES PB Health Secures $218 Million Seed Funding to Build Integrated Healthcare Ecosystem - https://lnkd.in/d2UCN4nk PM Modi Laun
Tech-Transfer and Manufacturing for Scaling Biotech - Landmark Bio Skip to content Services Process & Analytical Development Formulation Development Cell & Gene Therapy Manufacturing Fill & Finish Quality Control Testing CMC Regulatory & Drug Development Consulting IND-Enabling Services Technology Development Modalities & Technologies Viral Vectors Cell Therapies Nucleic Acids Extracellular Vesicles Nanoparticles & Non-viral Delivery Partnering Flexible Partnership Models Academia, Research Hospitals & Industry Blog About Our Story Facility Mission / Values O … at BLA stage, but the practical change will depend on how day-to-day reviewers apply it. Much of what’s in the announcement is a commitment to use tools that already exist, quality-by-design approaches, prior knowledge, platform data, more consistently. The proof, as one panelist put it, will be in the pudding. HEADQUARTERS 300 North Beacon Street Watertown, MA 02472 CONTACT US contact@landmarkbio
22q Gala – 22 q Skip to content Skip to content Facebook X YouTube Instagram Donate Shop My account Orders Cart Checkout News About Us Contact Us 22q Overview What is 22q Different Names For 22q Deletion vs. Duplication Diagnosis Genetics Symptoms & Care 22q Signs and Symptoms Adult Guidelines and Assessment Checklist Pediatric Guidelines and Assessment Checklist Developmental Skills Growth Charts Health Conditions Explained Health Guidelines Medical Treatment Resources Family Resources Physician Resources Get Involved 22q at the Zoo — Worldwide Awareness Day Talk About 22q Upcoming … l 22q11.2 Foundation’s mission to raise awareness, provide vital resources, and fund life-changing research. Your message will reach a wide audience of families, medical professionals, and advocates committed to supporting individuals with 22q11.2 deletion and duplication syndromes. What Can You Share? – Celebrate your child’s milestones and achievements – Share a message of love and encouragement – Honor your family’s strength and resilience – Inspire … n full color and included in the commemorative Program Book. Submission Details Deadline to Submit Ads: August 10, 2025 Midnight. How to Submit: Email photo along with wording to [email protected] Questions? Contact Carol Cavana at [email protected] or 877.739.1849 Make your mark and help us celebrate the global 22q community. Submit your ad today and help fill the Program Book with messages of love, hope, and unity. 22q Clinic and Family Support Organization Ads Support the “Aro … n full color and included in the commemorative Program Book. Submission Details Deadline to Submit Ads: August 10, 2025 Midnight. How to Submit: Email photo along with wording to [email protected] Questions? Contact Carol Cavana at [email protected] or 877.739.1849 Make your mark and help us celebrate the global 22q community. Submit your ad today and help fill the Program Book ! The International 22q11.2 Foundation is celebrating an amazing milestone as we proudly commemorate the 22nd
Autoimmune disease - Articles - Page 6 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib
Committees Skip to main content Home Info Committees Past Summits About IPITA Program Summit Evaluation Program Overview Detailed Program Call for Abstracts Invited Speakers Featured Speakers Posters Best Abstracts Session I Session II Session III Scientific Travel Awards Registration & Hotel Registration Accommodations Industry Confirmed Sponsors & Exhibitors Sponsor and Exhibitor Directory Support Contact Home Info Committees Past Summits About IPITA Program Summit Evaluation Program Overview Detailed Program Call for Abstracts Invited Speakers Featured Speakers Posters Best Abstract … cine. He completed General Surgery training as well as a post-doctoral research fellowship, at the University of Pennsylvania and Abdominal Organ Transplant Fellowship at University of Wisconsin. Dr. Odorico performed pancreas, islet and kidney transplants. He has an active, extramurally funded research laboratory that focuses on beta cell differentiation from pluripotent stem cells. He has previously served as President of IPITA and Chair of the UNOS Pancreas Committee. He i … inology, and Metabolic Diseases (DEM) at NIDDK. Within the Division of DEM, his grant portfolio includes studies that focus on the development and regeneration of the pancreatic endocrine compartment, as well as the application of this knowledge in stem cell differentiation and regenerative medicine. In addition, he participates in the Human Islet Research Network (HIRN), which organizes and supports collaborative research related to the loss of functional beta cell mass in t … ational Health & Medical Research Council (NH&MRC), The Medical Research Future Fund (MRFF) and the Juvenile Diabetes Research Foundation (JDRF). His work as a type 1 diabetes researcher is focused on islet transplantation and immunotherapy research. The aim is to challenge insulin replacement therapy for diabetes by introducing new treatments based on disease mechanisms. Eelco de Koning Netherlands Bio Bio is coming soon... Esther Latres United States Bio Scientist with exte … type 1 diabetes. His laboratory is supported by the NIH NIDDK and JDRF, and his scholarship has been recently recognized by awards from the JDRF, American Institute of Chemical Engineering, and the Biomedical Engineering Society. Cristina Nostro Canada Bio Bio is coming soon... Lorenzo Piemonti Italy Bio Bio is coming soon... Holger Russ United S
Participating Companies - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Sh … tion Family Office Financial Advising Financial, legal, consulting Hedge/Mutual Fund (PM,Buy-Side Research) Individual Investor Institute, hospital research Investment bank Investor (buy-side or sell-side research) IT, information Medical device or technology Other products or services Other R&D services Patient advocacy Public, NPO, govt., economic development Royalty/Debt Financing Supplier, engineering Synthesis, analytic, diagnostic services VC/Corporate VC Venture Philan … Therapeutics United States Flip Biotech or pharma, therapeutic R&D Flip Pangen Fund United States Flip Family Office Flip SC BIO United States Flip Public, NPO, govt., economic development Flip Arcera, ADQ company United Arab Emirates Flip VC/Corporate VC Flip Global Health Capital Fund Ireland Flip VC/Corporate VC Flip Massive Bio, Inc. United States Flip Digital health Flip Mint Pharma Capital United States Flip VC/Corporate VC Flip Miami Biotech Collective United States F … Public, NPO, govt., economic development Flip Rising Dragon Associates Vietnam Fund LP Flip Flip Saudi Ministry of Investment Saudi Arabia Flip Other products or services Flip Spring & Forge United States Flip Other products or services Flip Sutters.ai United States Flip Biotech or pharma, therapeutic R&D Flip The Leadership Edge, Inc United States Flip Flip Vivo Capital Taiwan Flip VC/Corporate VC Flip 8 Prime Biosciences Flip Flip AGED Diagnostics United States Flip Medica … nited States Flip Biotech or pharma, therapeutic R&D Flip BOLD Longevity Growth Fund United States Flip VC/Corporate VC Flip Breakthru Medicine's United States Flip Biotech or pharma, therapeutic R&D Flip Bridge United States Flip Other products or services Flip Bristol Myers Squibb United States Flip Flip Brilliance United States Flip Royalty/De
15 Oct 2024: Tolerance Bio, Inc. launches with $17.2 million in seed financing to advance thymus-based therapies for immune-mediated diseases Manifesto Portfolio Team News Contact EN ES CAT 15 Oct 2024: Tolerance Bio, Inc. launches with $17.2 million in seed financing to advance thymus-based therapies for immune-mediated diseases Related news No items found. We are looking to partner with transformative companies to shape the future of healthcare. Contact us Legal Terms Privacy Policy Legal Notice Cookies Policy Whistleblower channel Members © 2024 CriteriaCaixa
Tolerance Bio - 6th iPSC Drug Development Summit Skip to content Free to Attend for Biopharma & Academics* September 9-10, 2026 | Boston, MA About About the Summit FAQs Poster Session Content Hub iPSC Development in the Last 12 Months: Why This Year Matters More Than Most Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Day One Day Two Why Partner Why Partner Partners Media Partners Take Part Pricing & Registration Venue & Accommodation Contact Us Event Guide Register About About the Summit FAQs Poster Session Content Hub iPSC Development in the Last 12 Mont
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Portfolio News Tolerance Bio Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases By Webmaster October 15, 2024 December 11th, 2024 No Comments Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
生物制药公司Tolerance Bio获得1720万美元种子轮融资，以推进基于胸腺的免疫介导疾病疗法-动脉网 APP 扫码下载 产业链接 公众号矩阵 动脉网 动脉新医药 动脉橙果局 产业链接 VBEF发布 动脉生物制造 透皮技术创新联盟TTIA 动脉智库 活动会议 2025数字疗法大会 CSGCT第二届中国细胞与基因治疗大会 2026未来医疗100强大会 2025VBEF直播回放&百强榜单 全部活动 解决方案 动脉AI 搜索 EN 登录 首页 情报 原创 专题 报告 链接 直播 活动 动脉网APP 扫码下载 生物制药公司Tolerance Bio获得1720万美元种子轮融资，以推进基于胸腺的免疫介导疾病疗法 Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymusased Therapies for Immune-Mediated Diseases businesswire 等信源发布 2024-10-15 17:00 可切换为仅中文 微信扫码分享 PHILADELPHIA--(BUSINESS WIRE)--Tolerance Bio, Inc., a biopharmaceutical company pionee … 于Criteria Bio Ventures Criteria Bio Ventures is a leading life sciences venture fund investing in transformative companies to shape the future of healthcare. We partner with driven entrepreneurs and fellow investors to build innovative companies with the potential to transform patients’ lives. Criteria Bio Ventures invests in global biotech companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe. Crit … ut BioAdvance BioAdvance BioAdvance is an $80-million early-stage life sciences fund with a focus on the mid-Atlantic region, investing in companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed more than $73 million in funding to approximately 115 organizations developing more than 208 products in the diagnostics, therapeutic, medtech, research tools, and digital health sectors. BioAdvance是一个8000万美元的早期生命
agenda | Advanced Therapies USA Toggle navigation Advanced Therapies USA 2026 4 - 5 November Hynes Convention Center, Boston home our story agenda conference 2026 partners Clinician Hub Poster Application CPD Accreditation sponsors & exhibitors Sponsor/Exhibit Start-Up Application Download Prospectus Attendee Breakdown Speakers Apply to Speak register- offer ends july 24 contact us Accommodation FAQ Agenda Boston, 4 - 5 November 2026 Schedule Nov 4 Nov 5 Filter your schedule: Topics: Keynote (Keynote Theatre) Start-up Pitch (Seminar Theatre) Cell Therapy Manufacturing Sponsor … nsored by Cellares Corporation (Theatre 1) John Tomtishen, Global Head of Field Application Scientists and Strategic Alliances, Catalent Nov 4 14:55 Conference pass Insight on the Parkinson’s Disease Program: How targeting a genetic population enables entry into a larger market of sporadic PD? Gene Therapy (Theatre 5) Jennifer Johnston, Cofounder and CEO, NysnoBio Nov 4 14:55 Conference pass Leveraging RWE to support clinical development for orphan diseases Evidence, Pricing … racterisation in ovarian cancer Pre-Clinical & Clinical (Theatre 4) Kristin Grant Beaumont, Associate Professor, Icahn School of Medicine, Mount Sinai Nov 5 15:40 Conference pass IND preparedness for cell & gene therapies Regulatory Affairs & Policy (Track 3, Room 202) Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute Nov 5 15:40 Conference pass International standards for characterising and testing cell therapy products Cell Therapy Manufacturi … pendent Expert, Independent Expert Nov 5 16:20 Conference pass Optimization and application of HSV vectors Viral Vector Manufacturing (Theatre 3) Selene Ingusci, Research Instructor, University of Pittsburgh Nov 5 16:20 Conference pass Rewards and challenges of being a one-stop shop for cell therapy manufacturing in an academic medical center Pre-Clinical & Clinical (Theatre 4) Lynn O'Donnell, Director, Cell Therapy Manufacturing & Engineering, The Ohio State Univ … n for Patients in a Maturing CGT Landscape John Tomtishen, Global Head of Field Application Scientists and Strategic Alliances, Catalent John Tomtishen is a cell therapy industry veteran and recognized CMC leader within biopharmaceutical manufacturing having served in diverse business and technical roles throughout his career. John is currently t
Phil Ball - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Show more menu i
BioAdvance Capital | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors BioAdvance Capital BioAdvance Capital Conshohocken, Pennsylvania bioadvance.org Overview BioAdvance is an early-stage venture capital firm dedicated to advancing human health. They invest in therapeutics, medical devices, digital health, diagnostics, and research tools, primarily focusing on seed and Series A opportunities in the Mid-Atlantic region from New York City to Washington, D.C. BioAdvance pro
Tolerance Bio at Longevity Global Aging Code Summit | Yeh-Chuin Poh posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
Regeneration of the Atrophied Thymus is a Growing Field Once Again – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » October 24th, … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room | Resources | About Read our terms and conditions and privacy poli
Tolerance Bio - 9th Antigen-Specific Immune Tolerance Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 meeting. Returning March, 2026 | Boston, MA About About Event Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Partners Take Part Register Interest Contact Us 2026 Event Guide Register Interest About About Event Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Partners Take Part Register Interest Contact Us Returnin
Criteria Bio Ventures - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators
Beyond Celiac Investments Announces Investment in Tolerance Bio to Advance Novel Approach in Celiac Disease About About EIN Presswire How We Are Different. Better. How It Works Testimonials Company Ethos EIN Presswire in the News EIN Presswire on Substack EIN Presswire on Trustpilot Contact Pricing Distribution Distribution Overview Media Database Major News Sites U.S. TV & Radio Stations U.S. & International Newswires Newswires by Industry Newswires by Country Newswires by U.S. State Mobile Apps NewsPlugin Live Feed Sample Distribution Report Press Releases All Featured By Industry By … gram Questions? +1 (202) 335-3939 Pricing & Comparison Chart Contact Log In Submit Release News Search Search World Media Directory · RSS · Email Newsletters There were 1,132 press releases posted in the last 24 hours and 476,214 in the last 365 days. Beyond Celiac Investments Announces Investment in Tolerance Bio to Advance Novel Approach in Celiac Disease News Provided By Beyond Celiac June 22, 2026, 13:59 GMT Share This Article BCI’s second investment to … ce PR Distribution How It Works Why Us Pricing Distribution Compare PR Services Submit Release Newswires All Newswires World Newswires US Newswires Industry Newswires Press Releases All Press Releases Featured Releases by Industry Releases by Country Releases by US State Releases by Date Resources World Media Directory Mobile App Affiliate Program RSS Feeds Email Newsletters News Alert Maker NewsPlugin Help / Support FAQ Editorial Guidelines Video Tutorials Client Testimonial
✨ Thank you Ryan from Philadelphia Business Journal for covering the top Startups to look out for in 2025! A special shoutout to our portfolio companies, Naturaz and Tolerance Bio for making the… | Ben Franklin Technology Partners of Southeastern Pennsylvania LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies
Tolerance Bio and ZipCode Bio Partner on Thymus Therapeutics | Zipcode Bio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … y is the next frontier in RNA therapeutics,” commented Dr. Drew Weissman, Nobel Prize Laureate, pioneer of mRNA technology, and Co-Founder of ZipCode Bio. “Each advance in nucleic acid therapeutics has been built on decades of careful science. By partnering with Tolerance Bio, we have the opportunity to extend this work into thymus biology, an area with profound implications for immune health.” The collaboration will initially focus on preclinical development of thymus-target … y is the next frontier in RNA therapeutics,” commented Dr. Drew Weissman, Nobel Prize Laureate, pioneer of mRNA technology, and Co-Founder of ZipCode Bio. “Each advance in nucleic acid therapeutics has been built on decades of careful science. By partnering with Tolerance Bio, we have the opportunity to extend this work into thymus biology, an area with profound implications for immune health.” The collaboration will initially focus on preclinical development of thymus-target … ed into target cells in a predictable way. I am grateful for the opportunity to apply this promising science to help address cardiomyopathies like those driven by a mutation in the phospholamban ( #PLN ) gene. Learn more at souffletx.com #biotech #siRNA #nucleicacid #drugdiscovery #phospholamban #heartfailure Soufflé Therapeutics 7,598 followers 8mo Edited Scientists and investment firms that helped form Alnylam and CRISPR Therapeutics, leading companies in novel modalities,
BioAdvance Capital | Improving Human Health Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Improving Human Health We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life. ABOUT US LET'S TALK Continuing to Grow & Invest We are an evergreen fund that has a long-term investment perspective. OUR APPROACH LET'S TALK Focusing on the Mid-Atlantic Region We invest in life-science companies in the Mid-Atlantic region. OUR CRITERIA LET'S TALK
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cell
Investors and Partners | Grow with Us — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our T
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … aging and dysregulation." ZipCode Bio Search company , co-founded by Nobel Prize Laureate Dr. Drew Weissman, brings significant expertise in RNA therapeutics to the partnership. Dr. Weissman, who pioneered mRNA technology and received the 2023 Nobel Prize in Physiology or Medicine, emphasized the importance of precision delivery in advancing RNA therapeutics. "Precision delivery is the next frontier in RNA therapeutics," commented Dr. Weissman. "Each advan
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: S … linical Immunology Societies (FOCiS) from 2022-2024, a recipient of the Medawar Prize, and a member of the National Academy of Medicine. Dr. Camillo Ricordi, M.D., FNAI, is a Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant Center and … organizations, Dr. Ricordi has received numerous accolades, including the World Prize in Surgery, the American Diabetes Association’s Outstanding Scientific Achievement Award, the Leonardo Da Vinci Award, and induction into the National Academy of Inventors. His extensive contributions include over 1,170 publications, 58,000 citations, 28 patents, and the bestselling book The Healthspan Code . Dr. Jerome Ritz, M.D. ’s research focuses on immune reconstitution after hematopoie … ollow us on LinkedIn . About Pacific 8 Ventures Pacific 8 Ventures is a venture fund focusing at the nexus of new technology platforms and medicine. Pacific 8 Ventures typically backs transformative biotech and healthcare founders at the early stages. For more information, please visit: www.pac8.com Media Contact Kate Burdick Inizio Evoke Comms [email protected] 860-462-1569 Phil Ball Previous Previous Tolerance Bio and ZipCode Bio Announce Strategic R&D Collab
Tolerance Bio | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Category Tolerance Bio Jun 22 Love 0 Beyond Celiac Investments Announces Investment in Tolerance Bio to Advance Novel Approach in Celiac Disease By Gayle Mineo Portfolio News , Tolerance Bio BCI’s second investment to advance therapeutic treatments for celiac disease will support preclinical development of novel approach to immune tolerance AMBLER, PA, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- Beyond Celia
Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publicatio … Criteria Bio Ventures Criteria Bio Ventures is a leading life sciences venture fund investing in transformative companies to shape the future of healthcare. We partner with driven entrepreneurs and fellow investors to build innovative companies with the potential to transform patients’ lives. Criteria Bio Ventures invests in global biotech companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe. Crit … ; About BioAdvance BioAdvance is an $80-million early-stage life sciences fund with a focus on the mid-Atlantic region, investing in companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed more than $73 million in funding to approximately 115 organizations developing more than 208 products in the diagnostics, therapeutic, medtech, research tools, and digital health sectors. BioAdvance portfolio comp
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Recent News | Discover Latest Updates — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our T
What's Next in Beta Cell Function: Insights from the 85th Scientific Sessions | Recording false OasisLMS zh-CN,zh-TW,en,pt,es Login Skip Navigation Links Home My Courses My Education History DiabetesPro Menu Home My Courses My Education History DiabetesPro Hamburger Menu Catalog What's Next in Beta Cell Function: Insights from t ... What's Next in Beta Cell Function: Insights from the 85th Scientific Sessions | Recording Recorded Webinar Beta cell research is evolving rapidly—and the implications for clinical practice are closer than ever. Join the American Diabetes Association® for … g evidence on beta cell function will impact clinical care in the future. Apply insights on beta cell function to inform future patient care decisions. Speakers E. Danielle Dean, PhD Assistant Professor of Medicine and Molecular Physiology and Biophysics Vanderbilt University Medical Center Nashville, TN Dr. Danielle Dean is an Assistant Professor of Medicine and Molecular Physiology and Biophysics at Vanderbilt University School of Medicine. She
Tolerance Bio Inc. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
What's Next in Beta Cell Function: Insights from the 85th Scientific Sessions false OasisLMS zh-CN,zh-TW,en,pt,es Login Skip Navigation Links Home My Courses My Education History DiabetesPro Menu Home My Courses My Education History DiabetesPro Hamburger Menu WEBINAR What’s Next in Beta Cell Function: Insights from the 85th Scientific Sessions OVERVIEW Discover the future of diabetes care. Beta cell research is evolving rapidly—and the implications for clinical practice are closer than ever. Join the American Diabetes Association® for a thought-provo … g evidence on beta cell function will impact clinical care in the future. Apply insights on beta cell function to inform future patient care decisions. BENEFITS This is a non-CE webinar. Learners will benefit from direct access to leading experts and emerging insights on beta cell function from the ADA’s 85th Scientific Sessions. EXPIRATION DATE November 4, 2026 Register Now FACULTY Michael R. Rickels, MD., MS Professor of Medicine University of Pennsy
2024 International Celiac Disease Symposium Recap | Celiac Disease Foundation Skip to main content Sign Up for Email Updates Donate Search Search Back to Home Back to Home For Researchers Donate Search Search Celiac Disease Foundation --> About Celiac Disease About the Disease About the Disease What is Celiac Disease? Symptoms of Celiac Disease Testing & Diagnosis Treatment & Follow-Up Celiac Disease in Children Related Conditions & Mental Health Virtual Education Events Symptoms Assessment Tool Gluten-Free Resources Gluten-Free Resources What is Gluten? Label Reading & the FDA Eat! Gluten-Fre … Committee Leadership Join the iCureCeliac® Registry Qualify for a Celiac Trial Apply for a Research Award Get Involved Advocacy and Public Policy Advocacy and Public Policy Support the Celiac Safety Act Become a Policy Advocate 2026 Celiac Disease Awareness Month Proclamations 2026 Public Policy Agenda Our Collective Success Campaigns and Initiatives Policy Tracker Public Policy Resources Join the Effort Join the Effort Events Ways To Give Create a Fundraiser Run a Marathon … and Securities Employer Matching Other Ways to Give Venture Philanthropy Impact Fund Research Awards and Prizes Proud Sponsors and Partners Make a Donation Become a Research Partner Become a Proud Sponsor Menu Donate Sign Up for Email Updates! Search Search → About Celiac Disease About the Disease What is Celiac Disease? Symptoms of Celiac Disease Testing & Diagnosis Treatment & Follow-Up Celiac Disease in Children Related Conditions & Mental Health Virtual Education Eve … eCeliac Registry Data Join the iCureCeliac® Registry Qualify for a Celiac Trial Apply for a Research Award For Clinicians Research Awards and Prizes NASPGHAN Diagnosis Tool Patient Recruitment Services Scientific Advisory Committee Scientific Advisory Committee Leadership Join the iCureCeliac® Registry Qualify for a Celiac Trial Apply for a Research Award Get Involved Advocacy and Public Policy Support the Celiac Safety Act Become a Policy Advocate 2026 Celiac Disease Awarene … and Securities Employer Matching Other Ways to Give Venture Philanthropy Impact Fund Research Awards and Prizes Proud Sponsors and Partners Make a Donation Become a Research Partner Become a Proud Sponsor → Home About Why Join? About Filmmaker Hayley Repton Frequently Asked Questions Your Privacy Contact For Researchers Patient Recruitment &
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Tolerance Bio | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our Team Scientific Advisory Board Folder: Scientific
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and P … the next frontier in RNA therapeutics,” commented Dr. Drew Weissman, Nobel Prize Laureate, pioneer of mRNA technology, and Co-Founder of ZipCode Bio. “Each advance in nucleic acid therapeutics has been built on decades of careful science. By partnering with Tolerance Bio, we have the opportunity to extend this work into thymus biology, an area with profound implications for immune health.” The collaboration will initially focus on preclinical development of thymus-target
Our Publications — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our Team Scientific Adviso
Tolerance Bio | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymus 0 Skip to Content About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu About Our Team Scientific Advisory Board Scientific Focus The Thymus: School for T-Cells Team Publications Investors and Partners Recent News Contact Open Menu Close Menu Folder: About Back Our Team Scientific Advisory Board Folder: Scientific